Researchers and ethicists have long been concerned about the expectations for direct medical benefit expressed by participants in early phase clinical trials. Early work on the issue considered the possibility that participants misunderstand the purpose of clinical research or that they are misinformed about the prospects for medical benefit from these trials. Recently, however, attention has turned to the possibility that research participants are simply expressing optimism or hope about their participation in these trials. The ethical significance of this therapeutic optimism remains unclear. This paper argues that there are two distinct phenomena that can be associated with the term ‘therapeutic optimism’—one is ethically benign and the other is potentially worrisome. Distinguishing these two phenomena is crucial for understanding the nature and ethical significance of therapeutic optimism. The failure to draw a distinction between these phenomena also helps to explain why different writers on the topic often speak past one another.
- unrealistic optimism
- therapeutic misconception
- informed consent
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Funding Work on this paper was supported by an NIH-NCI grant # R21CA131601-01A1, Understanding Optimism in Clinical Research.
Competing interests None.
Provenance and peer review Not commissioned; externally peer reviewed.
Read the full text or download the PDF:
Other content recommended for you
- Unrealistic optimism and the ethics of phase I cancer research
- Understanding people’s ‘unrealistic optimism’ about clinical research participation
- Phase 1 oncology trials and informed consent
- Perceptions of control and unrealistic optimism in early-phase cancer trials
- Informed consent for early-phase clinical trials: therapeutic misestimation, unrealistic optimism and appreciation
- Therapeutic appropriation: a new concept in the ethics of clinical research
- Phase I oncology trials: why the therapeutic misconception will not go away
- Navigating choice in the face of uncertainty: using a theory informed qualitative approach to identifying potential patient barriers and enablers to participating in an early phase chimeric antigen receptor T (CAR-T) cell therapy trial
- Faith, Hope And (No) Clarity
- Therapeutic optimism in the consent forms of phase 1 gene transfer trials: an empirical analysis